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CASE REPORT 
Obstructive sleep apnoea following rapid weight 
gain secondary to treatment with vigabatrin (Sabril@) 
M.V. LAMBERT & J.M. BIRD 
Burden Neurological Hospital, Stoke Lane, Stapleton, Bristol, BS16 lQT, UK 
A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an 
increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described. The 
relationship between exacerbation of epilepsy and sleep disruption secondary to OSA is discussed. Recommenda- 
tions regarding the choice of anticonvulsants in patients at risk of developing OSA are made. 
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INTRODUCTION 
Weight gain is a known side-effect of treatment 
with the anticonvulsant vigabatrin (Sabril@)‘. 
This case shows the consequences of rapid weight 
gain, in the form of generalized pitting oedema in 
a person predisposed to developing obstructive 
sleep apnoea. 
CASE HISTORY 
CW is a 42-year-old married and employed man, 
with normal birth and development. He de- 
veloped idiopathic complex partial seizures with 
secondary generalization at the age of 16. There 
was no relevant past medical history including 
chest disease and no family history of epilepsy 
(although his son subsequently developed similar 
seizures in adulthood). His fits occurred ap- 
proximately weekly and were unresponsive to 
phenobarbitone, phenytoin, carbamazepine, eth- 
osuximide, lamotrigine and gabapentin. They 
were partially responsive to sodium valproate but 
he suffered a weight gain of 38 kg on this 
treatment. His fits were exacerbated by sleep loss 
secondary to worry about potential redundancy. 
He was a non-smoker and rarely consumed 
alcohol. He had a collar size of 18.5 inches (which 
had increased from 15 inches since early adult- 
hood), and a weight of 111.5 kg with a body mass 
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index of 34.5 kg/m2. He had a normal com- 
puterized tomography (CT) scan and electroen- 
cephalograph (EEG). His magnetic resonance 
imaging (MRI) scan however, showed a volume 
loss in the right hippocampus with temporal horn 
dilatation on the same side. 
Although he had no previous history of 
psychiatric illness, he developed episodes during 
which he felt low and tearful, but had a normal 
appetite and sleep pattern. He did not appear to 
be clinically depressed and these episodes were 
thought to be secondary to worry abut his 
seizures and potential redundancy. However 
because of these episodes of low mood, he was 
hospitalized for a trial of vigabatrin (Sabril@) 
as an adjunct to sodium valproate (Epilim 
Chrono@). As an inpatient, on 2g of vigabatrin, 
he was fit-free for 5 weeks and his mood 
improved to the extent that he felt able to resume 
his normal activities, so he was discharged home. 
Three weeks later, he was re-admitted as an 
emergency with excessive daytime sleepiness and 
restless nights. His wife reported that he had a 
disturbed nights sleep and had started snoring. 
He had also gained over 11 kg of weight over 
these three weeks (a 10.3% increase in his usual 
weight). The control of his epilepsy had deterior- 
ated and he was suffering weekly seizures. On 
admission, he was constantly falling asleep and 
had developed signs of fluid retention with 
generalized pitting oedema, tachycardia and 
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hypertension. There were no other signs of right 
heart failure. His electrocardiogram (ECG) and 
routine haematology and biochemistry were 
normal. EEG monitoring showed no epileptic 
activity but he repeatedly fell asleep, during 
which frequent periods of apnoea, each lasting 
approximately lo-15 s were noted. During the 
apnoeas, his oxygen saturation dropped to below 
70%; they were terminated by a snore. He was 
thought to have developed obstructive sleep 
apnoea (OSA) secondary to rapid weight gain, 
following treatment with vigabatrin. The vigabat- 
rin was reduced and then stopped and he was 
given one dose of the diuretic frusemide. His 
weight decreased by 7 kg in 4 days and he no 
longer had signs of fluid retention. His sleep 
pattern returned to normal with no snoring and 
no further seizures occurred. A repeat sleep- 
deprived EEG 4 days after admission, again 
showed periods of apnoea lasting up to 13 s; 
however, his oxygen saturation did not drop 
below 92%. When seen as an outpatient, 6 weeks 
after stopping vigabatrin, his weight had returned 
to 111 kg, and he had continued to have restful 
nights free from snoring and apnoeas. He had 
only experienced one seizure since discharge. 
DISCUSSION 
Vigabatrin is an irreversible inhibitor of gamma- 
aminobutyric acid (GABA) transaminase, and 
thus increases levels of GABA (the inhibitory 
neurotransmitter) in the brain. The main re- 
ported side-effects in adults are: somnolence, 
fatigue, irritability, dizziness, depression (4%), 
headache, confusion, poor concentration, ab- 
dominal pain and anorexia2. Psychiatric side- 
effects are seen in approximately 5%3, and 
psychosis with paranoid ideation occurs in around 
1.3-1.7%4, although Sander et al, found 14 out of 
210 patients developed a schizophrenia-like 
syndrome5. Tartara et al, in a 6-year follow-up 
study, found weight gain occurred in 12 out of 215 
(48%) patients in the first 12 months and varied 
between 5 and 33% of the initial weight’. 
Obstructive sleep apnoea occurs when the 
pharyngeal airway collapses during sleep. It 
occurs in l-9% of the population and is 
characterized by repetitive apnoeas, loud snoring 
and excessive daytime sleepiness. Other symp- 
toms include nocturnal choking attacks, morning 
headaches, nocturia, impotence, poor memory 
and concentration. Chronic OSA can result in 
hypertension, myocardial infarction, stroke and 
death6. Psychiatric disorders are also associated 
with OSA, including paranoid psychosis and 
depression. Treatment of the OSA may improve 
the patient’s cognitive and affective status’. The 
major risk factor for OSA in adults is obesity, as 
increased peripharyngeal soft tissue (in the form 
of neck fat deposition) reduces the calibre of the 
airway during sleep. Neck circumference >43 cm 
(17 inches) has been found to be a better 
predictor of risk than overall obesity’. Other risk 
factors in the adult include male sex, age, 
retrognathia, craniofacial abnormalities, nasal 
obstruction and sedatives (especially alcohol and 
benzodiazepines)6q9. 
In 1994, Devinsky et af” reported a series of 
seven patients with obstructive sleep apnoea and 
medically refractory epilepsy. They found that 
treatment of the OSA could reduce seizure 
frequency and severity. They commented that 
OSA may aggravate or precipitate seizures by 
causing sleep disruption and deprivation, hypo- 
xaemia, decreased cerebral blood flow and 
decreased cardiac output. Vaughn et al”, in 1996, 
also reported 10 patients with recurrent seizures 
and sleep disruption related to OSA. Treatment 
of the OSA alone (either by positional therapy or 
continuous positive airways pressure) resulted in 
a marked improvement in seizures in four 
patients. A further three patients had a reduction 
in seizure frequency following treatment of their 
OSA in combination with a change in anticonvul- 
sant medication. They concluded that treatment 
of OSA, in patients with epilepsy may lower the 
frequency of recurrent seizures. 
This patient had risk factors for the develop- 
ment of OSA (male sex and collar size >17 
inches). However, he only developed symptoms 
of OSA-snoring, apnoeas and excessive daytime 
somnolence-after experiencing rapid weight 
gain whilst taking vigabatrin. Since the weight 
gain and development of generalized pitting 
oedema coincided with starting vigabatrin and the 
weight loss and resolution of the oedema 
followed its reduction, it seems likely that the 
vigabatrin was responsible. The weight loss was 
both dramatic and rapid (7 kg in 4 days), which 
would imply that the weight gain was secondary 
to fluid retention rather than fat deposition. Thus, 
it would appear that treatment with vigabatrin 
produced fluid retention in the form of pitting 
oedema, and it was this oedema around the neck 
that was responsible for the OSA. Although his 
seizure frequency initially reduced on the com- 
bination of vigabatrin and valproate, it increased 
again following the development of OSA. When 
his sleep pattern returned to normal after 
stopping vigabatrin, his seizure frequency les- 
sened. This is in agreement with the findings of 
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Devinsky et aI” and Vaughn et al”, that sleep 
disruption secondary to OSA exacerbates epi- 
lepsy and treatment of the OSA can reduce 
seizure frequency. 
Since OSA may aggravate epilepsy and in itself 
be a cause of morbidity and mortality, caution 
should be exercised in prescribing anticonvulsant 
drugs that are known to have a side-effect of 
weight gain in patients with, or at risk of 
developing, OSA. 
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